Compare Dow Jones Industrial Average ETF (DIA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Recursion Pharmaceuticals Inc — how do they compare? Dow Jones Industrial Average ETF trades at $512.97 (market cap $45.20B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Dow Jones Industrial Average ETF is far larger — about 19.6× Recursion Pharmaceuticals Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DIA | RXRX | |
|---|---|---|
Market Cap | $45.20B | $2.31B |
Volume | 4,095,368 | 40,478,768 |
52-Week High | $542.79 | $6.79 |
52-Week Low | $451.37 | $2.84 |
Typical Hold Time | 103 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $511.02, down 0.68% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent dividend distributions provide income appeal, though key valuation metrics remain unavailable. Support levels cluster around $506-509 while resistance sits at $512-516.
The ETF faces near-term headwinds from technical weakness and broader market volatility. Dividend payments offer income stability, but lack of fundamental metrics limits valuation assessment. Market sentiment remains cautious amid economic uncertainty and Fed policy concerns.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
